Transthoracic echocardiography(TTE) revealed an ejection fraction (EF) of 55-60%, asymmetric septal hypertrophy of 18.92mm, hypokinesis of the inferoseptal myocardium, left ventricular outflow tract(LVOT) obstruction with mean gradient of 145mmHg, increased LVOT velocity
See our page here and blogs over the topic
Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for In a clinical trial, adults with obesity or overweight and a weight-related medical condition taking Zepbound 15 mg lost 48 lbs (~21% weight loss) and approximately 1 in 3 on Zepbound 15 mg lost over 58 lbs (25% weight loss) 1 Health care providers can begin prescribing the 12.5 mg and 15 mg vials on "Obesity is a serious, chronic disease, and access to obesity medications should be treated with the same urgency as other chronic conditions," said Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off

Intervention studies have shown that weight reduction in PwO through caloric restriction alone or in combination with low-impact aerobic exercise results in increased levels of BTMs and decreased BMD values [29, 30]